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centers of India. This will not only help in better 
management of the patients but also the approach is cost 
effective in long run as against the myth that such tests 
are unaffordable for developing world. 
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Respiratory viruses (RV) are a frequent cause of severe 
respiratory disease in BMT recipients. Few clinical and 
epidemiological data of RV infections are available in 
immunocompromised patients in South America. We 
conducted a prospective trial from April 2001 to January 
2002 to evaluate the frequency of respiratory viruses in 
BMT recipients. Nasal washes (NW) were collected in 
all patients with symptoms of upper respiratory tract 
infection (URI). Direct immunofluorescence assay 
(DAKO) was performed for antigen detection of RSV, 
influenza (Flu) A and B, adenovirus and parainfluenza 
(Paraflu) virus. Patients with established RSV pneu- 
monia and patients with RSV-URI infection before 
engraftment or those with acute GvHD grade 111 
received aerosolized ribavirin. Oseltamivir was given to 
all patients with influenza. One hundred ninety seven 
patients had 314 episodes of URI during the study 
period (mean 1,6 episodes per patient). The mean 
number of NW taken was 3,14 (1 to 16) per patient. 
Sixty-eight patients (34.5%) tested positive: RSV was 
detected in 15 patients (22%); Flu B in 18 (26.4%) Flu 
A in 14 (20.5%) and Paraflu in 4 (5.8%). Most frequent 
virus associations were RSV+Flu A, Flu A+Flu B and 
RSV+Flu B (5.8%; 5.8% and 4.4% respectively). The 
remaining 6 patients (8.8%) had other RV associations. 
RSV pneumonia developed in 12 of the 25 patients 
(48%) with RSV-URI. RSV related death was observed 
in 1 patient with pneumonia (8.3%). Flu B pneumonia 
was diagnosed in one patient (3.5%). Similarly to 
developed countries, RSV infections occurred during fall 
and early winter. Influenza viruses peaked in winter- 
spring months. Pre-emptive therapy with aerosolized 
ribavirin and oseltamivir probably contributed to the 
decreased rates of RSV related deaths and influenza 
pneumonia observed in the present study. 
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The polyomaviruses (BKV, JCV, and SV40) are 
ubiquitous agents that cause latent infection of the 
kidney with intermittent excretion in immune com- 
petent hosts and manifest disease during immune 
suppression. BKV causes nephropathy in adult renal 
transplant patients, and JCV is commonly found in the 
urine of healthy adults. Little is known about 
polyomavirus infection in pediatric patients with renal 
disease, although SV40 has been associated with 
pediatric renal transplantation by serologic testing and 
by direct detection of SV40 DNA in biopsy material. 
To test the hypothesis that polyomaviruses may be 
associated with pediatric renal disease, we enrolled 
children with NS (n=50) or immune compromise (HIV 
infection, acute lymphocytic leukemia or heart trans- 
plantation, n=36) in a prospective study of poly- 
omavirus infection as determined by polyomavirus PCR 
using buffy coat- and urine pellet-derived DNA samples, 
followed by virus-specific oligonucleotide hybridization. 
For comparison, we tested archival DNA samples from 
buffy coat specimens collected by the Diagnostic 
Virology Laboratory at Texas Children’s Hospital. 
There was no difference in the urinary excretion of 
polyomaviruses in total (JC virus, BK virus, or SV40), 
being present in 18 of 59 samples (30.5%) from children 
with NS and in 4 of 22 samples (18.2%) from children of 
the immune-compromised groups (p=O.43). Of 35 
children with renal disease, BKV, JCV, and SV40 were 
detected in the urine of 6,10 and 7 children, respectively. 
Among 15 children with immune compromise, BKV, 
JCV, and SV40 were detected in the urine of 2,2, and 0 
patients, respectively. Only SV40 excretion was found to 
be associated with renal disease (p=O.O3). From buffy 
coat samples, 8 of 26 children with renal disease were 
positive for SV40, whereas none contained detectable 
JCV or BKV DNA. Several children were identified 
with concurrent SV40 viremia and viruria. In contrast, 
none of 136 archival DNA samples from 86 children 
were positive for SV40 sequences (p<O.OOl). 
Taken together, these data suggest an association of 
SV40 polyomavirus infection with pediatric renal 
disease. Further studies are required to delineate the 
pathophysiologic and prognostic significance of SV40 
infection in children with renal disease and after renal 
transplantation. 
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For high-risk CMV-seronegative liver transplant 
recipients with CMV-seropositive donors, 100 days of 
post-transplant intravenous (IV) ganciclovir has been 
the most effective regimen for prophylaxis of CMV 
disease but is limited by the need for prolonged IV 
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access. Thus, in this controlled trial, following induction 
with 14 days of IV ganciclovir (6mg/kg IV qd), CMV- 
seronegative liver transplant recipients with CMV-sero- 
positive donors were randomized to receive either 
oral ganciclovir (1000 I mg 18hrs, Mon-Sun) or IV 
ganciclovir (6 mg/kg qd, Mon-Fri) until day 100 after 
transplant. Patients were followed until time of death or 
12 months after transplant. CMV disease occurred in 
3/32 oral ganciclovir patients (9.3%) and in 4/32 IV 
ganciclovir patients (12S%).Types of CMV disease: oral 
ganciclovir (syndrome 2, hepatitis 1); IV ganciclovir 
(syndrome 3, hepatitis + colitis l).There were no deaths 
from CMV in either study group. All cases of CMV 
disease occurred > 90 days after transplant (median time 
of onset day+137 for oral ganciclovir and day+135 for 
IV ganciclovir). Both oral and IV ganciclovir were well- 
tolerated. Reversible leukopenia (WBC <3000/mm3) 
occurred in 9/32 oral ganciclovir patients (28.1%) and in 
12/32 IV ganciclovir patients (37.5%) but did not require 
withdrawal of any patient from the study. Emergence of 
ganciclovir-resistant strains of CMV was not found 
during the study. These results suggest that, following 
induction with 2 weeks of IV ganciclovir, oral ganciclovir 
can be as effective as IV ganciclovir for long-term CMV 
prophylaxis in high-risk CMV-seronegative liver 
transplant patients with CMV-seropositive donors and 
eliminate the need for prolonged IV access. 
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Two hundred and sixteen HD patients (M:102, F:114, 
aged 4517212.84) received recombinant hepatitis B 
vaccine (Combiotech Ltd, Russia) or Engerix B. The 
protocol of vaccination scheduled 4 doses of 40 Kg at O- 
l-2-6 months. Before the end of vaccination 13 pts (6%) 
had acute hepatitis B. HBsAb levels in this group was 
~100 IU/L after the 3 mos. 27 pts (13%) at the end of 
vaccination had HBcoreAB. The efficacy of vaccination 
was evaluated by the determination HBsAb levels after 
3 and 7 mos from the beginning of immunization in 176 
pts.The frequency of seroconversion (HBsAb level from 
10 to 99 IU/L) after 3mos was 23% and it was 13% after 
7 mos. The rate of seroprotection (HBsAb level 2100 
IU/L) after 3 mos reached 50% and increased up to 70% 
after 7 mos. Relation between some factors involved in 
immune response and vaccination efficiency in 46 pts 
was studied. In patients with HBsAb level ~100 IU/l 
count CD3 lymphocytes were 0.84+0.1 109/1, CD20- 
0.36+0.04 109/1, and concentration of IL-l-2.78+0.63 
pmol/ml, IL-2 -13.36+ 1.97 pmol/ml, IgM - 0.84+0.14 g/l. 
In patients with HBsAb levels 2100 IU/l these values 
were significantly different (~~0.05) and were equal to 
0.9520.16 109/1, 0.41?0.05 109/1, 3.22kO.77 pmol/ml, 
15.9623.2 pmollml, 1.120.24 g/l, respectively. Logistic 
regression analysis and criteria tables method permitted 
to determine the predictors of low efficacy of 
vaccination in HD patients: amount CD20 lymphocytes 
<3.5(109/~, concentration IgM +0.95 rr/rr, IL-2 512 
pmol/ml, transferrin in blood >2.8 g/L. The presence of 
two and more from these parameters allows the 
prognosis of negative or low response to vaccination. 
Sensitivity and specificity of such prognosis equal 86% 
and 84%, respectively. 
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Introduction: Systemic infections due to Listeria 
monocytogenes are infrequent but serious complications 
in patients with an underlying malignancy. Institution of 
appropriate therapy is critical in improving outcome 
especially in patients with profound defects in cellular 
immunity. 
Methods: In vitro antimicrobial susceptibility profiles of 
84 clinical isolates of L. monocytogenes from patients 
with listeric infections during 1955 to 1997 at Memorial 
Sloan-Kettering Cancer Center in New York were 
reviewed retrospectively. 
Results: The 84 L. monocytogenes isolates showed 
greater than ninety percent in vitro susceptibility to 
penicillin (97.6%) ampicillin (90.7%) erythromycin 
(98.8%) tetracycline (96.9%), and gentamicin (98.0%). 
No in vitro resistance was observed for trimethoprim- 
sulfamethoxazole (TMP-SMX), rifampin, amikacin, 
vancomycin, imipenem/cilastatin, and ciprofloxacin. 
High-level resistance to clindamycin (96.2%) and 
amoxicillin/clavulanate (100%) was unexpected. The 
MI& and MIC9o among 26 L. monocytogenes during 
1991 to 1997 for penicillin and ampicillin were 0.5 and 
1.0 kg/ml respectively. During this period MI&, for 
gentamicin, imipenem/cilastatin, and ciprofloxacin was 
5 1.0 Fg/ml. 
Conclusions: Since 1955, we observed no interval in- 
crease in resistance for penicillin, ampicillin, gentamicin 
and TMP-SMX among L. monocytogenes in our high- 
risk listeric patients. Amoxicillin/clavulanate does not 
appear to be an adequate choice for oral therapy in this 
setting. The newer antimicrobial compounds such as 
